Fig. 1 · Structure

Documents & Downloads

ASP3026

Cat. No. A11773 CAS 1097917-15-1

ALK inhibitor

ASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-kinase panel.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
ALK 3.5 nM

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 IC50 1508 nM Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay [PMID: 33243531]
BaF3 IC50 17 nM Inhibition of EML4-fused ALK variant 1 (unknown origin) expressed in mouse BAF3 cells using peptide substrate measured after 1 hr by HTRF assay [PMID: 30878193]
BaF3 IC50 323.9 nM Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay [PMID: 33243531]

ASP3026 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of ASP3026 from 3 published references. In vitro models include K299; PfLysRS. In vivo models include female C.B-17 SCID mice.

ASP3026 In Vitro Studies

ASP3026 had a cell proliferation IC50 of 19 nM in K299 cells after 72 hours. In the PfLysRS ATP hydrolysis assay, its IC50 was 965 nM. In SU-DHL-1 cells, the MTS viability IC50 was 0.4 μM after 48 h. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell proliferation in K299

Cell-based study · K299 [1]

K299 cells were exposed to serial dilutions of ASP3026 for 72 hours. The cell proliferation IC50 was 19 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell proliferation rateIC50 K299; 72 hours: IC50 19 nM[1]

Literature-Reported Treatment Conditions

Exposure duration
72 hours
Method
in the presence of serial dilutions of compounds
Vehicle
0.5% final DMSO concentration
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: ASP3026

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

METHODS > Proliferation assay (S121, S122, S124, S125); Table 1 (T1.h1, T1.r1)

cell proliferation rate: cell proliferation rate; comparator: vehicle-treated control — METHODS > Proliferation assay (S121, S124); Table 1 (T1.h1, T1.r1)

ATP hydrolysis in a PfLysRS assay

Cell-based study · PfLysRS [2]

PfLysRS was incubated with ASP3026 and assessed using an ATP hydrolysis assay. The IC50 was 965 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP hydrolysis assaysIC50 IC50 was 965 nM[2]

Literature-Reported Treatment Conditions

Exposure duration
mixed with compounds and incubated for 10 min. Then 5 μL substrate mixture (2 μM ATP, 10 μM l-lysine and 31 nM pyrophosphatase) was added to start the reaction at 37 °C and incubated for 6 h.
Method
mixed with compounds
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: ASP3026

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Substitution of the 4-(4-methylpiperazinyl)piperidinyl moiety significantly improved the selectivity against PfLysRS in vitro (S24); Methods > ATP hydrolysis assays (S152, S156, S157, S160)

ATP hydrolysis assays: ATP hydrolysis assays; comparator: DMSO was added into negative control wells and l-lysine was removed in positive control wells — Results > Substitution of the 4-(4-methylpiperazinyl)piperidinyl moiety significantly improved the selectivity against PfLysRS in vitro (S24); Methods > ATP hydrolysis assays (S152)

Cell viability in SU-DHL-1

Cell-based study · SU-DHL-1 [3]

SU-DHL-1 cells were treated with the compound for 48 h and assessed using an MTS viability assay. The IC50 was 0.4 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
viability of all NPM-ALK+ ALCL cell lines tested, as measured by MTS assayIC50 48 h: IC50 0.4 μM in SU-DHL-1[3]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Vehicle
DMSO admixed with H2O and HCl (1:1)
Reported limits
Not stated in the sentences used: dose, route.
Methods and source locations

Compound reported in the paper: ASP3026

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > ASP3026 decreases NPM-ALK+ ALCL cell viability (S1, S3, S4); METHODS > ALK inhibitor (S58); METHODS > MTS assay (S61)

viability of all NPM-ALK+ ALCL cell lines tested, as measured by MTS assay: viability of all NPM-ALK+ ALCL cell lines tested, as measured by MTS assay; comparator: T lymphocytes that were used as a negative control — RESULTS > ASP3026 decreases NPM-ALK+ ALCL cell viability (S1, S3)

ASP3026 In Vivo Studies

Female SCID mice injected with Karpas 299 cells received uninterrupted ASP3026 by oral gavage or vehicle control. Mean ± SE survival was 79.8 ± 8.0 days with ASP3026 versus 43.1 ± 3.3 days with vehicle control. [3]

Survival in mice injected with Karpas 299 cells

Animal study · female C.B-17 SCID mice (6-8 weeks old; Taconic, Cambridge City, IN) [3]

Female SCID mice injected with Karpas 299 cells received uninterrupted ASP3026 by oral gavage. Mean ± SE survival was 79.8 ± 8.0 days with ASP3026 versus 43.1 ± 3.3 days with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
overall survivaloverall survival 79.8 ± 8.0 days[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
at 3 weeks after injection of Karpas 299 cells; administered uninterruptedly for 10 weeks
Vehicle
0.5% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ASP3026 30 mg/kg dailyControl mice were given vehicle (0.5% methylcellulose).mice treated with uninterrupted ASP3026 (U) lived 79.8 ± 8.0 days; the mean ± SE duration of survival in control mice was 43.1 ± 3.3 days; P = 0.001 in ASP3026 [U] vs. control or CHOP[3]
ASP3026 30 mg/kg daily
Model: female C.B-17 SCID mice (6-8 weeks old; Taconic, Cambridge City, IN)
Methods and source locations

Compound reported in the paper: ASP3026

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

METHODS > ALK inhibitor (S58); METHODS > Systemic xenograft NPM-ALK+ ALCL model (S95, S97, S99, S100, S101, S102); Figure 5 legend (S179, S181, S186)

overall survival: overall survival; comparator: Control mice were given vehicle (0.5% methylcellulose). — Figure 5 legend (S179, S181, S186)

ASP3026 30 mg/kg daily · METHODS > Systemic xenograft NPM-ALK+ ALCL model (S100, S101); Figure 5 legend (S179, S181, S186)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1097917-15-1
Applications ALK inhibitor
Formula C29H40N8O3S
Molecular Weight 580.7
SMILES
CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC=NC(=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 13 mg/mL (22.38 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ASP3026 Research References

  1. [1] Mologni L, Ceccon M, Pirola A, et al. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget (2015). PMID: 25749034 DOI: 10.18632/oncotarget.3122 Source material
  2. [2] Zhou J, Xia M, Huang Z, et al. Structure-guided conversion from an anaplastic lymphoma kinase inhibitor into Plasmodium lysyl-tRNA synthetase selective inhibitors. Commun Biol (2024). PMID: 38890421 DOI: 10.1038/s42003-024-06455-4 Source material
  3. [3] George SK, Vishwamitra D, Manshouri R, et al. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget (2014). PMID: 25026277 DOI: 10.18632/oncotarget.2170 Source material

Added to your cart

View Cart Checkout
Loading...